Recent Posts

1. 

   Amneal

   Can this even be legal? Who is doing the recruiting, and are they internal candidates from other divisions? Does HR know this is happening? If so, I am appalled.

   Impax Labs/Global

   anonymous

   Jun 1, 2024 at 9:17 PM

2. 

   Interviewing with Esperion with cardiology background

   Dude I’d probably wait a while to see how things shake out. There’s a lot of talk about us being bought out and nobody knows what that would mean for legacy ESPR, Certainly a great cadre of reps here but no guess what Novartis, Merck, Pfizer, DS...

   Esperion

   anonymous

   Jun 1, 2024 at 9:02 PM

3. 

   Evidence of Opportunities Within vs. Evidence of Opportunities Externally

   https://en.m.wikipedia.org/wiki/Bottom_feeder

   Alnylam Pharmaceuticals

   anonymous

   Jun 1, 2024 at 8:58 PM

4. 

   Describe Morale in 3 words

   If you don't like it, leave!

   AstraZeneca

   anonymous

   Jun 1, 2024 at 8:58 PM

5. 

   Tanking Stock

   Leadership isn’t promised dog shit. Especially 2-3 years. This company is worth 1B at best so stop with the day dreams. If another aesthetic company acquires this shithole, only the top reps survive. We all know this, just not all wants to admit...

   Revance Biotech

   anonymous

   Jun 1, 2024 at 8:53 PM

6. 

   Sotyktu floundering

   Cut the dals and rmks and half the managers And the 20 laziest reps and replace them with more reps now that could make business sense

   Bristol-Myers Squibb

   anonymous

   Jun 1, 2024 at 8:52 PM

7. 

   karuna deal

   Beware of the Avanir job hooper toxicity train rolling into this opportunity. Former Avanir mgrs love to bring their toxic posse with them from job to job.

   Bristol-Myers Squibb

   anonymous

   Jun 1, 2024 at 8:48 PM

8. + Show More